A Randomly Controlled Clinical Trial of Aspirin-vitamin C Dispersible Tablets in Patients with Acute Upper Respiratory Tract Infection

苏欣,施毅,宋勇,谢增华,赵蓓蕾,辛晓峰,曹鄂洪,肖鑫武
DOI: https://doi.org/10.3760/cma.j.issn.1008-1372.2005.07.008
2005-01-01
Abstract:Objective To evaluate the efficacy and safety of Aspirin-vitamin C dispersible tablets in treating upper respiratory tract infection (URI). [WTHZ]Methods Forty-five patients with URI were included in the present trial. Twenty-three patients were treated with Aspirin-vitamin C dispersible tablets, and the other matched twenty-two patients were treated with Bayaspirin-vitamin C effervescent tablets. Results The efficient rate in the two groups receiving the first single dose of Aspirin-vitamin C or Bayaspirin-vitamin C was 78.3% and 77.3%, respectively (P=1.0). There was no statistical difference in overall efficient rate between the two groups (82.6% vs 94.5%, P0.05). The incidence of side effect in the two groups was low, and had not significant difference between the two groups (4.4% vs 0%,P0.05). Conclusion Aspirin-vitamin C dispersible tablets is effective and safe for treating patients with URI.
What problem does this paper attempt to address?